+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute pancreatitis - Pipeline Insight, 2024

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • April 2024
  • Region: Global
  • DelveInsight
  • ID: 4835329
This “Acute pancreatitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Acute pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Acute pancreatitis Understanding

Acute pancreatitis: Overview

Acute pancreatitis is common and is the leading cause of hospitalization amongst gastrointestinal disorders in the United States. The severity of the disease varies widely, from mild disease needing conservative treatment to severe and complicated disease with high morbidity and mortality. The diagnosis of acute presentation is easy, but the major challenge is predicting the progression of disease course and outcome. This is important to determine the level of care. In the majority of cases, alcohol use, gallstones, and hypertriglyceridemia cause acute pancreatitis. The rate of occurrence of each etiology of acute pancreatitis varies across geographic regions and socioeconomic strata. Overall, the frequency of acute pancreatitis has been noted to be rising in the United States and the rest of the world. Whether this trend is related to a true increase in incidence or simply increased detection is difficult to determine. The rise in incidence is considered, in part, due to increased hypertriglyceridemia and metabolic syndrome, with multiple reports showing an increase in acute pancreatitis secondary to hypertriglyceridemia. The diagnosis of acute pancreatitis has been defined by the Revised Atlanta Classification and requires at least 2 of 3 criteria be met: 1) a lipase or amylase level that is three times the upper limit of normal 2) abdominal pain that is consistent with pancreatitis 3) abdominal imaging consistent with acute pancreatitis.

Acute pancreatitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute pancreatitis pipeline landscape is provided which includes the disease overview and Acute pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Acute pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Acute pancreatitis.
  • In the coming years, the Acute pancreatitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence Acute pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Acute pancreatitis treatment market. Several potential therapies for Acute pancreatitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Acute pancreatitis market size in the coming years.
  • This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Acute pancreatitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acute pancreatitis Emerging Drugs Chapters

This segment of the Acute pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute pancreatitis Emerging Drugs

Auxora: Calci Medica Inc.CalciMedica’s lead product candidate, Auxora TM (formerly CM4620), a proprietary intravenous-formulated CRAC channel inhibitor, is being developed for several indications including the treatment of respiratory distress syndrome associated with COVID-19, acute respiratory distress syndrome (ARDS) due to other types of pneumonia, predicted severe acute pancreatitis and other acute inflammatory diseases associated with dysregulation of intracellular calcium in organ tissues like the lung, pancreas or kidneys. Currently, it is in Phase II stage of clinical trial evaluation to treatacutepancreatitis.

Acute pancreatitis: Therapeutic Assessment

This segment of the report provides insights about the different Acute pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute pancreatitis

There are approx. 5+ key companies which are developing the therapies for Acute pancreatitis. The companies which have their Acute pancreatitis drug candidates in the most advanced stage, i.e. phase II include, Calci MedicaInc..

Phases

This report covers around 5+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Acute pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute pancreatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute pancreatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute pancreatitis drugs.

Acute pancreatitis Report Insights

  • Acute pancreatitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute pancreatitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Acute pancreatitis drugs?
  • How many Acute pancreatitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute pancreatitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute pancreatitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute pancreatitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • JD BIOSCIENCE
  • Cypralis
  • Regeneron Pharmaceuticals
  • SCM Lifescience
  • High TideTherapeutics

Key Products

  • GM 10134
  • CC-4066
  • EVINACUMAB
  • Pancreatitis stem cell therapy
  • HTD4010
Please note: The report will be dispatched within 2-3 days

Table of Contents

IntroductionExecutive Summary
Acute pancreatitis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Acute pancreatitis - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  • Comparative Analysis
Auxora: CalciMedica Inc.
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  • Comparative Analysis
Acute pancreatitis Key CompaniesAcute pancreatitis Key ProductsAcute pancreatitis- Unmet NeedsAcute pancreatitis- Market Drivers and BarriersAcute pancreatitis- Future Perspectives and ConclusionAcute pancreatitis Analyst ViewsAcute pancreatitis Key CompaniesAppendix
List of Tables
Table 1 Total Products for Acute pancreatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Acute pancreatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • JD BIOSCIENCE
  • Cypralis
  • Regeneron Pharmaceuticals
  • SCM Lifescience
  • HighTide Therapeutics